Sigle August, Gratzke Christian, Grabbert Markus
Medizinische Fakultät, Klinik für Urologie, Universitätsklinikum Freiburg, Hugstetter Straße 55, 79106, Freiburg im Breisgau, Deutschland.
Medizinische Fakultät, Berta-Ottenstein-Programm, Universität Freiburg, Freiburg im Breisgau, Deutschland.
Urologie. 2023 May;62(5):529-539. doi: 10.1007/s00120-023-02081-w. Epub 2023 Apr 28.
The systemic treatment of advanced prostate cancer (PCa) has undergone an absolute revolution in the past decade. Numerous new substances have been approved for all stages of advanced disease and treatment has been increasingly intensified. The focus continues to be on substances with an effect on the androgen receptor axis. In this review, approved treatment options for metastatic hormone-sensitive PCa (mHSPC), non-metastatic castration-refractory PCa (nmCRPC) and metastatic castration-refractory PCa (mCRPC) are summarized. A special focus is on novel hormone therapeutic agents. Based on recent trial data, potential triple combinations for mHSPC as well as treatment sequence options and novel targeted agents for mCRPC are also highlighted.
在过去十年中，晚期前列腺癌（PCa）的全身治疗发生了彻底变革。众多新药物已被批准用于晚期疾病的各个阶段，治疗也日益强化。重点仍然是对雄激素受体轴有作用的药物。在本综述中，总结了转移性激素敏感性PCa（mHSPC）、非转移性去势抵抗性PCa（nmCRPC）和转移性去势抵抗性PCa（mCRPC）的已批准治疗方案。特别关注新型激素治疗药物。基于近期试验数据，还重点介绍了mHSPC可能的三联组合以及mCRPC的治疗顺序选择和新型靶向药物。
